Lantern Pharma Inc. (NASDAQ: LTRN) has introduced a new artificial intelligence module designed to predict the effectiveness of cancer treatment combinations involving DNA-damaging agents and DNA damage response inhibitors. The technology integrates into the company's RADR platform, which supports AI-guided drug development, positioning Lantern Pharma as a developer of data-driven approaches to oncology drug development.
The module enhances clinical success probabilities and aligns with industry efforts to personalize cancer treatments based on molecular and genetic profiles. This advancement represents a significant step in transforming the cost, pace, and timeline of oncology drug discovery and development through artificial intelligence and machine learning technologies.
Lantern Pharma's proprietary RADR platform leverages over 200 billion oncology-focused data points and a library of more than 200 advanced machine learning algorithms to address real-world problems in cancer drug development. The company has accelerated its growing pipeline of therapies spanning multiple cancer indications, including both solid tumors and blood cancers, through this AI-powered approach.
The company's drug programs typically advance from initial AI insights to first-in-human clinical trials within 2-3 years at approximately $2.5 million per program, significantly reducing both development time and costs compared to traditional methods. Additional information about Lantern Pharma's developments is available in the company's newsroom at https://ibn.fm/LTRN.
This AI module development demonstrates the growing role of artificial intelligence in modern drug discovery, particularly in oncology where personalized treatment approaches are becoming increasingly important. The technology's ability to predict treatment effectiveness could lead to more targeted and efficient cancer therapies, potentially improving patient outcomes while reducing development costs and timelines for new cancer treatments.
